设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH研究的应用及单片复方制剂(SPC)在高血压治疗中的地位--Weber教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:ACCOMPLISH 单片复方制剂 倍博特 阿利吉仑 


International Circulation:  Is SPC a reasonable choice in diabetics with hypertension in antihypertensive therapy?

国际循环:对合并糖尿病的高血压患者,SPC是否是合理的降压选择?

Michael Weber:  We found that in a very large number of diabetic patients, in fact over half the patients in ACCOMPLISH did have type II diabetes, that these approaches to therapy were extremely efficacious.  These patients finished with very well reduced blood pressure.  I was gratified that both the amlodipine/RAAS blocker, and the hydrochlorothiazide/RAAS blocker were both very effective in our diabetic patients.  So, yes, for people with diabetes, people with different ethnic backgrounds, as far as we could see it didn’t matter if people were Caucasian, if they were black, if they were of Asian origin, everyone seemed to get very very effective blood pressure reduction.

Michael Weber教授:事实上ACCOMPLISH中超过半数合并2型糖尿病,这种疗法对大多数糖尿病患者非常有效。研究结束时,这些患者的血压得到很好控制。氨氯地平/RAAS阻断剂与双氢克尿噻/RAAS阻断剂都可以有效降低糖尿病患者的血压。因此,无论对高加索人、黑人还是亚洲人糖尿病患者,都能良好降压。



上一页  [1]  [2]  [3]  [4]  [5]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved